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Abstract: Cancer cells have been reported to exhibit an enhanced capacity for   protoporphyrin IX 
(PpIX) synthesis facilitated by the administration of 5-aminolevulinic acid (ALA). We   investigated 
the effect of ALA-based photodynamic therapy (PDT) on human cholangiocarcinoma cells 
(HuCC-T1). Since protoporphyrin IX (PpIX), a metabolite of ALA, can produce reactive oxygen 
species (ROS) under irradiation and then induce phototoxicity, ALA-based PDT is a promis-
ing candidate for the treatment of cholangiocarcinoma. When various concentrations of ALA 
(0.05–2 mM) were used to treat HuCC-T1 cells for 6 or 24 hours, the intracellular PpIX level 
increased according to the ALA concentration and treatment time. Furthermore, an increased 
amount of PpIX in HuCC-T1 cells induced increased production of ROS by irradiation, result-
ing in increased phototoxicity.
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Introduction
Cholangiocarcinoma (CC) is the second most common primary hepatobiliary 
  malignancy in adults, and has high mortality. It often arises from background condi-
tions that cause longstanding inflammation, injury, and reparative biliary epithelial 
cell proliferation, such as primary sclerosing cholangitis, clonorchiasis, hepatolithiasis, 
or complicated fibropolycystic diseases.1–5 The most common curative therapy for 
CC is surgical resection. However, the majority of patients are diagnosed in a latent 
CC state and, unfortunately, they are not considered for surgery. For this reason, 
alternative therapies such as stent replacement, chemotherapeutic, radiation therapy, 
and photodynamic therapy (PDT) are the treatments of choice for the management 
of CC.6–9 PDT typically involves systemic administration of a tumor-localizing pho-
tosensitizer followed by its activation by light of an appropriate wavelength to create 
a photochemical reaction, thus causing photodamage to the tumor.10,11
5-aminolevulinic acid (ALA) is a precursor of PpIX, which is well known as a strong 
photosensitizer, and administered ALA is interconverted to PpIX via the heme biosyn-
thetic pathway.12–15 PpIX accumulation in tumor cells is generally higher than that in 
normal cells, as the activity of key enzymes in tumor cells is significantly changed.16–18 
Excitation of PpIX under irradiation in tumor cells can produce a significant amount of 
reactive oxygen species (ROS), including singlet oxygen, superoxide, hydroxyl radical, 
and hydrogen peroxide. ROS causes DNA and cell membrane damage through lipid 
peroxidation and/or alterations in membrane fluidity. This reaction results in obvious 
damage to cellular organelles, such as mitochondria and microsomes,19–22 and causes 
the death of tumor cells.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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One of the main advantages of ALA-based PDT is 
that ALA-derived PpIX is cleared from the body within 
24–48 hours after systemic ALA administration. This fact 
reduces or avoids the risk of prolonged phototoxicity to the 
human body.14–17 Recently, researchers reported the effects 
of ALA-based PDT in various tumor cells such as oral 
squamous cell carcinoma, melanoma, glioma, lymphoma, 
esophageal carcinoma, and basal cell carcinoma.10,23–27 ALA 
and its derivatives are therefore considered a potential treat-
ment option for hepatobiliary cholangiocarcinoma therapy.
In this study, the effect of ALA treatment on PpIX 
  synthesis, ROS production, and cell death in cholangiocarci-
noma cells was investigated. To the authors’ knowledge, there 
has been no in vitro study of the potential of ALA-based PDT 
in HuCC-T1 cells. Since ALA is regarded as safe for PDT 
compared with other photosensitizers, the application of ALA-
based PDT will provide a new treatment option for CC.
Methods
Materials
5-aminolevulinic acid (ALA), 2′, 7′-dichlorofluorescein 
diacetate (DCFH-DA), 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromid (MTT), and propidium iodide 
(PI) were purchased from Sigma-Aldrich Co (St Louis, MI). 
FITC-Annexin V was obtained from Santa Cruz Biotech-
nology, Inc (Santa Cruz, CA). Cell culture materials were 
purchased from Invitrogen (New York, NY).
cell culture
The human intrahepatic cholangiocarcinoma cell line 
(HuCC-T1) was used in this study. The cells were routinely 
propagated in Gibco® RPMI medium supplemented with 10% 
fetal bovine serum and 1% antibiotics at 37°C in a humidified 
atmosphere of 5% CO2:95% air according to the procedure 
described by Miyagiwa et al.1 Every 3 days, trypsin-EDTA 
(0.05% trypsin and 0.02% EDTA) was used for subculture.
Dark toxicity
HuCC-T1 cells (1 × 104) were seeded into a 96-well plate 
and treated with various concentrations (0.05–2 mM) of 
ALA in serum-free medium for 6 or 24 hours. After that, 
the medium was changed to growth medium containing 10% 
fetal bovine serum and incubated for 24 hours. Cell viability 
was measured by MTT assay.28
PpIX accumulation assay
HuCC-T1 cells were treated with various concentrations of 
ALA for 6 or 24 hours. After that, cells were lysed using cell 
lysis buffer (GenDEPOT, Barker, TX). PpIX accumulation 
in the cells was measured by fluorescence intensity using 
a microplate reader (Infinite M200 Pro, Tecan Group Ltd, 
Mannerdorf, Switzerland) at an excitation wavelength of 
485 nm and emission wavelength of 635 nm.
Light sources for photodynamic therapy
Cultured cell plates were exposed to LED lamps at 635 nm for 
irradiation (SH System Co, Gwangju, Korea). Light intensity 
was 0.25 J/cm2, as measured by a photo radiometer (Delta 
Ohm, Padua, Italy).
cell viability assay
HuCC-T1 cells were treated with various concentrations of 
ALA in serum-free medium for 6 or 24 hours. After incu-
bation with ALA, the cells were irradiated at 635 nm with 
0.25 J/cm2. The medium was changed to growth medium con-
taining 10% fetal bovine serum and incubated for 24 hours. 
Cell viability was measured by MTT assay.28
rOs measurement
After irradiation, ROS generation by PpIX-accumulated 
HuCC-T1 cells was measured by the DCFH-DA method.29 
In this method, fluorogenic substrate DCFH-DA, a cell-
permeable dye, is oxidized to highly fluorescent DCF by 
ROS, and can be used to monitor intracellular generation 
of ROS. The cells were treated with various concentra-
tions (0.05–2 mM) of ALA for 24 hours in phenol red 
free RPMI media. DCFH-DA was added to the media at 
a final concentration of 20 µM and incubated at 37°C for 
30 minutes. After irradiation at 635 nm, ROS generation 
was measured by fluorescence intensity at an excitation 
wavelength of 485 nm and emission wavelength of 535 nm 
using a microplate reader.
Flow cytometry analysis
Two reagents, PI and FITC-annexin V , were used to identify 
apoptosis and necrosis of HuCC-T1 cells, respectively. Cells 
were treated with various concentrations of ALA for 24 hours. 
After that, cells were irradiated at 635 nm with 0.25 J/cm2, 
then collected cells were washed with phosphate-buffered 
saline (PBS). The pellets were resuspended with binding 
buffer (10 mM 4-(2-hydroxyethyl)-1-piperazineethanesul-
fonic acid [HEPES] pH 7.4, 150 mM NaCl, 5 mM KCl, 
1 mM MgCl2, 1.8 mM CaCl2) containing FITC-annexin V 
(1 ug/mL) and further incubated for 30 minutes. Ten minutes 
prior to termination of incubation, PI (10 ug/mL) was added 
to stain necrotic cells under dark conditions. Following that, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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the cells were immediately analyzed using a FACScan flow 
cytometer (Becton Dicknson Biosciences, San Jose, CA).
Fluorescence microscopy
PpIX products were observed by fluorescence   microscopy. 
The microscope (Eclipse 80i; Nikon, Tokyo, Japan) was 
equipped with a 460–480 mm excitation filter and a 
610 nm filter for detection of PpIX fluorescence. 1 × 106 
HuCC-T1 cells were seeded on a cover glass in a 6-well 
plate. The cells were then treated with 0.25 mM ALA for 
24 hours in serum-free media, after which the medium was 
discarded and washed with PBS. The cells were fixed by 4% 
paraformaldehyde in PBS, mounted on a glass slide, and 
observed using a fluorescence microscope.
Phase contrast microscopy
Cell death by ALA-PDT was observed by phase contrast 
microscopy (MCXI 600; Micros, Vienna, Austria). 1 × 106 
HuCC-T1 cells were seeded in a 6-well plate. The cells were 
then treated with 0.25 mM ALA for 24 hours in serum-free 
media.
statistical analysis
All the experiments in this study were performed in tripli-
cate, ie, average plus standard deviation value was obtained 
from three independent experiments. All data are shown as 
the mean ± SEM of the independent experiments. Statistical 
analysis was performed using Student’s t-test (SPSS Data 
Collection [IBM Corp, Somers, NY] software). Statistical 
significance was taken as P , 0.001.
Results
Dark toxicity of hucc-T1 cells by ALA
To identify dark toxicity, various concentrations of ALA 
were treated to HuCC-T1 cells for 6 or 24 hours without 
radiation (Figure 1). When the HuCC-T1 cells were incubated 
with less than 0.5 mM ALA for 6 hours or 0.25 mM ALA 
for 24 hours, their survivability did not significantly change, 
ie, more than 90% of cells survived. Dark toxicity of cells 
appeared at greater than 0.5 mM at 6 hours treatment and 
0.25 mM at 24 hours treatment.
PpIX production by ALA
PpIX accumulation in HuCC-T1 cells incubated with ALA 
was assessed for 6 or 24 hours. Production of PpIX in 
HuCC-T1 cells was extremely high after 24 hours treat-
ment with 1 mM ALA (Figure 2A). PpIX accumulation in 
HuCC-T1 cells induced by 0.25 mM ALA treatment for 
24 hours was observed by phase contrast and fluorescence 
confocal microscopy. As shown in Figure 2B, red fluores-
cence was observed in the sample treated with 0.25 mM ALA, 
but no fluorescence signal was observed in the control group. 
These results indicate that administered ALA could be suc-
cessfully interconverted to PpIX in HuCC-T1 cells.
cell death induced by ALA-PDT
First, cell death by ALA-PDT was measured by MTT assay. 
HuCC-T1 cells were treated with ALA at various concentra-
tions for 6 or 24 hours. The survivability of HuCC-T1 cells 
after   irradiation was significantly decreased by 1 mM ALA 
treatment for 6 hours and 0.5 mM ALA for 24 hours, as shown 
in Figure 3A. When the exposure time of tumor cells to ALA 
was increased, photocytotoxicity increased in a similar range. 
Second, cell death induced by ALA-PDT in HuCC-T1 cells was 
identified by photomicrographs, as shown in Figure 3B. Whereas 
cell density was clearly decreased by treatment with 0.25 mM 
ALA, control treatment resulted in many cells. These results 
indicate that ALA-PDT induces death of HuCC-T1 cells.
Apoptosis and necrosis  
induced by ALA-PDT
After ALA-based PDT, tumor cells were stained with FITC-
  annexin V for apoptotic cells (Figure 4A) and PI for necrotic 
cells (Figure 4B). As shown in Figure 4, the number of apop-
totic cells gradually increased according to the increase in 
ALA   concentration. Furthermore, the number of necrotic cells 
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Figure 1 cell dark toxicity by ALA treatment in hucc-T1 cells. hucc-T1 cells 
were treated with ALA (0, 0.05, 0.1, 0.25, 0.5, 1, 2 mM) in serum-free culture 
medium. These cells were incubated for 24 hours in normal media containing 10% 
FBs. cell survival was determined by measuring MTT. hucc-T1 cells treated with 
ALA concentrations of 0.5 mM for 6 hours and 0.25-mM for 24 hours did not 
significantly influence cell survival (.90%).
Abbreviations: ALA, 5-aminolevulinic acid; hucc-T1, human cholangiocarcinoma 
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also dramatically increased according to ALA concentration   
(Figures 4A, 4C). These results indicate that ALA-based 
PDT induces death of HuCC-T1 cells through apoptosis 
and necrosis.
rOs generation by ALA-PDT
As shown in Figure 4D, the ROS level gradually increased as 
the ALA concentration was increased to 0.5 mM after ALA-
based PDT. These results could be explained by the fact that 
synthesis of PpIX after 24 hours incubation was saturated above 
0.5 mM ALA. Therefore, ROS were produced by   ALA-PDT, 
and the ROS level increased according to the increase in ALA 
concentration. In addition, ROS generation by ALA-based 
PDT was associated with cell death (Figures 3A, 4D).
Discussion
Administration of ALA both in vitro and in vivo is known to 
enhance PpIX synthesis in cancer cells. Frank et al reported 
that PpIX accumulation in cancer cells is significantly higher 
than that in normal human fibroblasts.18 After irradiation, the 
PpIX-accumulated tumor cells produced ROS, which destroy 
tumor cells by apoptosis or necrosis.20–22,30 The advantage 
of ALA-based PDT is its ability to target tumor cells. ROS 
generation in cancer cells can be specifically amplified by 
local irradiation even though ALA is distributed throughout 
the whole body.
Recently, researchers have reported that ALA-based 
PDT can effectively inhibit tumor cell growth and enhance 
patient survivability. Inoue et al reported massive apoptotic 
cell death in human glioma cells after ALA-based PDT.27 
Furthermore, the efficacy of ALA-based PDT was reported 
in melanoma cells10 and oral squamous cell carcinoma.11
The main obstacle to the treatment of CC is the fact that 
CC develops deeper than the skin, making application of 
chemotherapy and radiotherapy difficult. ALA-based PDT 
has advantages in that ALA can be delivered locally by endo-
scopic operation, which allows for specific accumulation of 
PpIX in the tumor cells.31 Furthermore, local application of 
ALA-based PDT by endoscopic operation enables avoidance 
of the undesirable side effects of photosensitizers compared 
with systemic application.
Before ALA-based PDT using HuCC-T1 cells was 
tested, it was confirmed whether the cell death effect was 
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Figure 2 PpIX accumulation graph induced by ALA treatment for 6 or 24 hours in 
hucc-T1 cells (A) and photomicrographs of PpIX accumulation induced by ALA 
(0.25 mM) or non-treatment in hucc-T1 cells (B).
Abbreviations: ALA, 5-aminolevulinic acid; hucc-T1, human cholangiocarcinoma 
cells; PpIX, protoporphyrin IX.
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Figure  3  effect  of  ALA-PDT  in  hucc-T1  cells  (A)  and  photomicrographs  of 
hucc-T1 cell death by ALA-PDT (B).
Abbreviations: ALA-PDT, 5-aminolevulinic acid-photodynamic therapy; hucc-T1, 
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caused only by photoinduced cytotoxicity. The cytotoxicity 
of ALA in the absence of a light source (without irradia-
tion and dark conditions) was investigated. When the ALA 
concentration was less than 0.5 mM at 6 hours incubation, 
the survivability of HuCC-T1 cells did not significantly 
change, ie, more than 90% of tumor cells survived as shown 
in Figure 1. Furthermore, a similar result was observed at a 
greater incubation time and lower dose, ie, 24 hours incu-
bation at 0.25 mM ALA also did not significantly affect 
cell survivability. The viability of tumor cells decreased at 
more than 0.5 mM ALA at 6 hours incubation. Moreover, 
when the incubation time was increased to 24 hours, the 
effective dose of ALA decreased; ie, viability of tumor cells 
decreased at 0.25 mM ALA. In the absence of irradiation, 
ALA itself did not affect cell survivability at any concentra-
tion. PpIX accumulation induced by ALA in HuCC-T1 cells 
reached its maximum at 1 mM ALA (Figure 2A). These 
results indicate that the ALA-based-PDT effect against 
human cholangiocarcinoma cells is dependent on the ALA 
concentration and incubation time. In addition, apoptosis 
and necrosis was identified in HuCC-T1 cells by ALA-PDT 
using FITC-annexin V and PI. The numbers of apoptotic 
and necrotic cells gradually increased on treatment with 
1 mM ALA for 24 hours, indicating that the viability of 
HuCC-T1 cells decreased (Figure 4). This result corre-
sponds with the fact that PpIX accumulation was maximal 
at 1 mM ALA. Although the necrosis of tumor cells was 
dominant over apoptosis as shown in Figure 4, secondary 
necrotic cells/late apoptotic cells might have been present 
in the necrotic population, since these secondary necrotic/
late apoptotic cells represent cells that were initially apop-
totic before losing membrane integrity due to a lack of 
timely phagocytosis. Even though apoptosis/necrosis dual 
staining did not strictly differentiate secondary necrotic/
late apoptotic cells from necrosis of tumor cells, the results 
show a positive corelationship between apoptosis/necrosis 
of tumor cells and cell death. Furthermore, ROS generation 
in HuCC-T1 cells gradually increased upon treatment with 
1 mM ALA for 24 hours (Figure 5). This result supports 
ALA-dependent death of HuCC-T1 cells after 24 hours 
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Figure 4 Apoptosis, necrosis, and rOs generation induced by ALA-PDT in hucc-T1 cells. After ALA or nontreatment for 24 hours, hucc-T1 cells were illuminated at 635 nm. 
cells were stained with FITc-annexin V (A) and propidium iodide (B) and analyzed using a flow cytometer. Arrows indicate direction of graph movement. (C) This graph displays 
percentage (%) of cells in M (dotted line) area of total cells. After irradiation, ROS production in the cells was immediately measured by fluorescence intensity (D). 
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incubation as shown in Figure 3A. After 6 hours   incubation 
with various concentrations of ALA, the   survivability of 
cells gradually decreased, and a significant decrease in 
cell survival was observed after 24 hours incubation with 
0.5 mM ALA. These results indicate that ROS generation 
by PDT in HuCC-T1 cells is simultaneously dependent on 
incubation time and ALA concentration. Cao et al reported 
that hematoporphyrin, a photosensitizer similar to ALA, 
exhibits a PDT-mediated cytotoxic effect against human 
cholangiocarcinoma cells both in vitro and in vivo.32 The 
results of the authors’ study show that ALA-based PDT is 
no less effective for treatment of human cholangiocarcinoma 
than hematoporphyrin.
In conclusion, a positive relationship between ALA 
concentration, PpIX accumulation, ROS production, and cell 
death by ALA-based PDT was observed. The results indicate 
that an appropriate concentration of ALA and treatment time 
is required to maximize the effects of ALA-based PDT and to 
minimize side effects. It is concluded that ALA-based PDT 
is a promising treatment option for CC.
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